Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis

被引:0
作者
Y. Xu
C. S. Yang
Y. J. Li
X. D. Liu
J. N. Wang
Q. Zhao
W. G. Xiao
P. T. Yang
机构
[1] First Affiliated Hospital,Department of Rheumatology and Immunology
[2] China Medical University,Department of 1st Cancer Institute
[3] First Affiliated Hospital,undefined
[4] China Medical University,undefined
来源
Clinical Rheumatology | 2016年 / 35卷
关键词
Amyopathic dermatomyositis; Biomarkers; Comorbidity; Rheumatic diseases;
D O I
暂无
中图分类号
学科分类号
摘要
Clinically amyopathic dermatomyositis (CADM) is a unique subset of dermatomyositis, showing a high incidence of lung involvements. The aim of this study is to identify risk factors, other than melanoma differentiation-associated protein (MDA)-5, for developing rapidly progressive-interstitial lung disease (RP-ILD) in patients with CADM. Forty CADM patients, in whom 11 patients developed RP-ILD, were enrolled. Clinical features and laboratory findings were compared between the patients with and without RP-ILD. We found that skin ulceration, CRP, serum ferritin, anti-MDA5 Ab, and lymphocytopenia were significantly associated with ILD. Multivariate logistic regression analysis indicated that anti-MDA5 Ab+, elevated CRP, and decreased counts of lymphocyte were independent risk factors for RP-ILD, which can provide a precise predict for RP-ILD in CADM patients. When anti-MDA5 Ab+ was removed from the multivariate regression model, using skin ulcerations, elevated serum ferritin and decreased counts of lymphocyte can also precisely predict RP-ILD. Except for MDA-5, more commonly available clinical characteristics, such as skin ulcerations, serum ferritin, and count of lymphocyte may also help to predict prognosis in CADM.
引用
收藏
页码:113 / 116
页数:3
相关论文
共 50 条
[11]   Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis [J].
Ho So ;
Victor Tak Lung Wong ;
Virginia Weng Nga Lao ;
Hin Ting Pang ;
Ronald Man Lung Yip .
Clinical Rheumatology, 2018, 37 :1983-1989
[12]   Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis [J].
So, Ho ;
Wong, Victor Tak Lung ;
Lao, Virginia Weng Nga ;
Pang, Hin Ting ;
Yip, Ronald Man Lung .
CLINICAL RHEUMATOLOGY, 2018, 37 (07) :1983-1989
[13]   HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients [J].
Jing Zou ;
Qiang Guo ;
Jiachang Chi ;
Huawei Wu ;
Chunde Bao .
Clinical Rheumatology, 2015, 34 :707-714
[14]   HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients [J].
Zou, Jing ;
Guo, Qiang ;
Chi, Jiachang ;
Wu, Huawei ;
Bao, Chunde .
CLINICAL RHEUMATOLOGY, 2015, 34 (04) :707-714
[15]   Interstitial lung diseases associated with amyopathic dermatomyositis [J].
Suda, T. ;
Fujisawa, T. ;
Enomoto, N. ;
Nakamura, Y. ;
Inui, N. ;
Naito, T. ;
Hashimoto, D. ;
Sato, J. ;
Toyoshima, M. ;
Hashizume, H. ;
Chida, K. .
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (05) :1005-1012
[16]   A Clinical Risk Model to Predict Rapidly Progressive Interstitial Lung Disease Incidence in Dermatomyositis [J].
Li, Yimin ;
Li, Yuhui ;
Wang, Yuguang ;
Shi, Lianjie ;
Lin, Fuan ;
Zhang, Zongxue ;
Zhang, Jingli ;
Liu, Yanying ;
Liu, Xu ;
Xu, Fangjingwei ;
Sun, Xiaolin .
FRONTIERS IN MEDICINE, 2021, 8
[17]   Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease [J].
Gono, Takahisa ;
Kaneko, Hirotaka ;
Kawaguchi, Yasushi ;
Hanaoka, Masanori ;
Kataoka, Sayuri ;
Kuwana, Masataka ;
Takagi, Kae ;
Ichida, Hisae ;
Katsumata, Yasuhiro ;
Ota, Yuko ;
Kawasumi, Hidenaga ;
Yamanaka, Hisashi .
RHEUMATOLOGY, 2014, 53 (12) :2196-2203
[18]   Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split? [J].
Satoshi Ikeda ;
Machiko Arita ;
Mitsunori Morita ;
Satoshi Ikeo ;
Akihiro Ito ;
Fumiaki Tokioka ;
Maki Noyama ;
Kenta Misaki ;
Kenji Notohara ;
Tadashi Ishida .
BMC Pulmonary Medicine, 15
[19]   Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split? [J].
Ikeda, Satoshi ;
Arita, Machiko ;
Morita, Mitsunori ;
Ikeo, Satoshi ;
Ito, Akihiro ;
Tokioka, Fumiaki ;
Noyama, Maki ;
Misaki, Kenta ;
Notohara, Kenji ;
Ishida, Tadashi .
BMC PULMONARY MEDICINE, 2015, 15
[20]   Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease [J].
Li, Xiaomeng ;
Liu, Yongmei ;
Cheng, Linlin ;
Huang, Yuan ;
Yan, Songxin ;
Li, Haolong ;
Zhan, Haoting ;
Li, Yongzhe .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (11)